Craig Hunsaker Sells 33,602 Shares of Alphatec (NASDAQ:ATEC) Stock

March 11, 2026 by InsiderTrades.com

Key Points

EVP Craig Hunsaker sold 33,602 ATEC shares on March 6 at an average price of $12.22 for about $410,616, trimming his stake by 1.82% to 1,808,974 shares (≈$22.1M).
Alphatec beat Q4 EPS ($0.06 vs. $0.04) and reported revenue up 20.4% year‑over‑year, while analysts hold a consensus "Moderate Buy" with an average target of $22.82—well above the current ~ $12.5 share price.
Multiple senior insiders (including General Counsel Tyson Marshall and additional Hunsaker sales) disclosed sizable recent sales totaling millions, a near‑term negative signal even as institutional ownership remains high (~66%).

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) EVP Craig Hunsaker sold 33,602 shares of the firm's stock in a transaction on Friday, March 6th. The stock was sold at an average price of $12.22, for a total value of $410,616.44. Following the transaction, the executive vice president owned 1,808,974 shares of the company's stock, valued at approximately $22,105,662.28. This represents a 1.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Alphatec Price Performance

ATEC opened at $12.51 on Wednesday. The stock's 50-day moving average price is $15.61 and its 200 day moving average price is $16.96. Alphatec Holdings, Inc. has a 12-month low of $8.81 and a 12-month high of $23.29. The firm has a market cap of $1.89 billion, a price-to-earnings ratio of -13.17 and a beta of 1.02. The company has a current ratio of 2.06, a quick ratio of 1.28 and a debt-to-equity ratio of 40.35.

Alphatec (NASDAQ:ATEC - Get Free Report) last issued its quarterly earnings results on Tuesday, February 24th. The medical technology company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.02. The business had revenue of $212.93 million for the quarter, compared to analyst estimates of $212.67 million. During the same period in the prior year, the company posted ($0.23) EPS. The firm's revenue for the quarter was up 20.4% compared to the same quarter last year. As a group, sell-side analysts expect that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have recently issued reports on ATEC shares. Wall Street Zen upgraded Alphatec from a "hold" rating to a "buy" rating in a research note on Saturday, January 31st. HC Wainwright reaffirmed a "buy" rating and issued a $24.00 price target on shares of Alphatec in a research report on Monday, January 12th. Morgan Stanley set a $23.00 price objective on Alphatec in a research report on Tuesday, December 2nd. Lake Street Capital reaffirmed a "buy" rating on shares of Alphatec in a report on Wednesday, February 25th. Finally, Stifel Nicolaus reduced their price objective on shares of Alphatec from $24.00 to $20.00 and set a "buy" rating on the stock in a report on Monday. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $22.82.

View Our Latest Research Report on Alphatec

Institutional Investors Weigh In On Alphatec

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Assenagon Asset Management S.A. grew its holdings in shares of Alphatec by 7,083.2% during the third quarter. Assenagon Asset Management S.A. now owns 750,429 shares of the medical technology company's stock worth $10,911,000 after purchasing an additional 739,982 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Alphatec by 2.4% in the 3rd quarter. Vanguard Group Inc. now owns 6,815,058 shares of the medical technology company's stock valued at $99,091,000 after purchasing an additional 158,295 shares during the period. American Century Companies Inc. boosted its position in shares of Alphatec by 6.0% in the 2nd quarter. American Century Companies Inc. now owns 6,177,161 shares of the medical technology company's stock valued at $68,567,000 after purchasing an additional 347,130 shares during the period. Lisanti Capital Growth LLC purchased a new position in Alphatec during the 3rd quarter worth approximately $3,305,000. Finally, SG Americas Securities LLC acquired a new position in Alphatec during the third quarter worth approximately $1,115,000. 66.35% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Alphatec

Here are the key news stories impacting Alphatec this week:

Positive Sentiment: Quarterly results and analyst support: Alphatec beat Q4 EPS estimates and reported +20% revenue growth year‑over‑year (Feb. 24), and multiple firms maintain buy ratings; consensus price target remains materially above the current price (~$22.82). MarketBeat Coverage
Positive Sentiment: Institutional accumulation: Several large funds (Millennium, Morgan Stanley, Tudor, Granite) materially increased stakes over recent quarters, signaling confidence from hedge funds/asset managers. Institutional Trading Details
Neutral Sentiment: Analyst price‑target change: Stifel lowered its target from $24 to $20 but retained a Buy rating — still optimistic but less aggressive on upside. Benzinga Article
Neutral Sentiment: Short interest postings show 0 shares / NaN changes for early March — likely a data or reporting quirk rather than a true change in short positioning; not meaningful by itself. (March 9–10 updates)
Negative Sentiment: Insider selling by senior executives: General Counsel Tyson Eliot Marshall sold 88,835 shares at an average $12.49 (total ~$1.11M) and EVP Craig Hunsaker sold 33,602 and 82,765 shares on March 6 and March 9 (~$410k and ~$1.03M). These disclosures show notable reductions in insider holdings and are commonly viewed as near‑term negative signals. SEC filings: Marshall Form 4 and Hunsaker Form 4

About Alphatec

(Get Free Report)

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company's portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec's flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.